Study record · Retatrutide
Retatrutide Phase 2a MASLD liver-fat substudy
At week 24, mean liver-fat changes were -42.9%, -57.0%, -81.4% and -82.4% versus +0.3% placebo; 79% and 86% at 8/12 mg reached <5% liver fat.
Key result
At week 24, mean liver-fat changes were -42.9%, -57.0%, -81.4% and -82.4% versus +0.3% placebo; 79% and 86% at 8/12 mg reached <5% liver fat.
Study details
Study designRandomized double-blind placebo-controlled substudy
PhasePhase IIa
PopulationAdults with obesity/overweight and MASLD with >=10% liver fat
Sample size98
RouteSubcutaneous
Regimen / exposure1, 4, 8 or 12 mg once weekly
Duration48 weeks
ComparatorPlacebo
Primary endpoint / questionRelative change in liver fat
Safety resultSafety profile arose within the parent obesity trial; GI and heart-rate signals remain relevant.
Key limitationsSubstudy sample is much smaller than the main obesity trial; liver-fat improvement is not yet an approved MASLD indication.
Registry / identifierPMID 38858523 / NCT04881760